Clareo Health | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
InflaRx GmbH
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent.
Subjects must be 18 years or older at the time of signing the informed consent.
You may not be if
Subjects with known severe or life-threatening hypersensitivity reaction to any other CSU/HS treatment according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE).
Subjects who have any other skin disease that may interfere with assessment of CSU or HS.
Subjects who have an active infection or history of infection(s) as follows:
1. Any infection requiring systemic treatment within 14 days prior to baseline.
2. A history of opportunistic, recurrent, or chronic infections that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
Subjects with known progressed liver disease (Child-Pugh B or C)
